Cerus Phase IIIc Intercept data

In a U.S. double-blind Phase IIIc study comparing plasma treated with CERS's Intercept Blood System to untreated plasma in 35 patients with thrombotic thrombocytopenic purpura (TTP), Intercept met the primary endpoint of no statistical difference in the proportion of patients achieving remission at 30 days after plasma exchange (82% for Intercept vs. 89% for control). Intercept also met the secondary endpoints, which included time to first remission, relapse rates and plasma exchange volume. ...